Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 225,000 Ordinary shares of 25 pence each.
- Purchase Date: October 26, 2011.
- Price Range: Highest price paid was 1,393.0 pence per share; lowest price paid was 1,385.0 pence per share.
- Treasury Holdings (Settled): 508,489,248 shares (9.13% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,289,248 shares (10.06% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,062,771,112 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 225,000 shares for Treasury. Consequently, the percentage of shares held in Treasury relative to total voting rights increased to 10.06% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (508,489,248 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,062,771,112 shares in issue) for disclosure threshold assessments.
- Check the settlement status of the 800,000 shares included in the "including shares which have been purchased but not yet settled" figure to reconcile the difference between settled and total treasury holdings.